134 related articles for article (PubMed ID: 31239188)
1. The impact of surgery for metastatic pancreatic neuroendocrine tumor: a contemporary evaluation matching for chromogranin a level.
Concors SJ; Sinnamon AJ; Ecker BL; Metz DC; Vollmer CM; Fraker DL; Roses RE
HPB (Oxford); 2020 Jan; 22(1):83-90. PubMed ID: 31239188
[TBL] [Abstract][Full Text] [Related]
2. Standard pre- and postoperative determination of chromogranin a in resectable non-functioning pancreatic neuroendocrine tumors--diagnostic accuracy: NF-pNET and low tumor burden.
Jilesen AP; Busch OR; van Gulik TM; Gouma DJ; Nieveen van Dijkum EJ
Dig Surg; 2014; 31(6):407-14. PubMed ID: 25572908
[TBL] [Abstract][Full Text] [Related]
3. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases.
Han X; Zhang C; Tang M; Xu X; Liu L; Ji Y; Pan B; Lou W
Eur J Gastroenterol Hepatol; 2015 May; 27(5):527-35. PubMed ID: 25822862
[TBL] [Abstract][Full Text] [Related]
4. Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors.
Hijioka M; Ito T; Igarashi H; Fujimori N; Lee L; Nakamura T; Jensen RT; Takayanagi R
Cancer Sci; 2014 Nov; 105(11):1464-71. PubMed ID: 25220535
[TBL] [Abstract][Full Text] [Related]
5. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
[TBL] [Abstract][Full Text] [Related]
6. Impact of chromogranin A, differentiation, and mitoses in nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm.
Mirkin KA; Hollenbeak CS; Wong J
J Surg Res; 2017 May; 211():206-214. PubMed ID: 28501118
[TBL] [Abstract][Full Text] [Related]
7. Predictive Value of Chromogranin A and a Pre-Operative Risk Score to Predict Recurrence After Resection of Pancreatic Neuroendocrine Tumors.
Fisher AV; Lopez-Aguiar AG; Rendell VR; Pokrzywa C; Rocha FG; Kanji ZS; Poultsides GA; Makris EA; Dillhoff ME; Beal EW; Fields RC; Panni RZ; Idrees K; Smith PM; Cho CS; Beems MV; Maithel SK; Winslow ER; Abbott DE; Weber SM
J Gastrointest Surg; 2019 Apr; 23(4):651-658. PubMed ID: 30659439
[TBL] [Abstract][Full Text] [Related]
8. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors.
Shanahan MA; Salem A; Fisher A; Cho CS; Leverson G; Winslow ER; Weber SM
J Surg Res; 2016 Mar; 201(1):38-43. PubMed ID: 26850182
[TBL] [Abstract][Full Text] [Related]
9. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.
Yao JC; Pavel M; Phan AT; Kulke MH; Hoosen S; St Peter J; Cherfi A; Öberg KE
J Clin Endocrinol Metab; 2011 Dec; 96(12):3741-9. PubMed ID: 21994954
[TBL] [Abstract][Full Text] [Related]
10. Measurement of circulating transcript levels (NETest) to detect disease recurrence and improve follow-up after curative surgical resection of well-differentiated pancreatic neuroendocrine tumors.
Genç CG; Jilesen APJ; Nieveen van Dijkum EJM; Klümpen HJ; van Eijck CHJ; Drozdov I; Malczewska A; Kidd M; Modlin I
J Surg Oncol; 2018 Jul; 118(1):37-48. PubMed ID: 30114319
[TBL] [Abstract][Full Text] [Related]
11. Plasma Chromogranin A as a Prognostic Marker in Pancreatic Ductal Adenocarcinoma.
Lee SH; Jo JH; Kim YJ; Lee HS; Chung MJ; Park JY; Bang S; Park SW; Song SY
Pancreas; 2019; 48(5):662-669. PubMed ID: 31091213
[TBL] [Abstract][Full Text] [Related]
12. Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors.
Pulvirenti A; Rao D; Mcintyre CA; Gonen M; Tang LH; Klimstra DS; Fleisher M; Ramanathan LV; Reidy-Lagunes D; Allen PJ
HPB (Oxford); 2019 May; 21(5):612-618. PubMed ID: 30366884
[TBL] [Abstract][Full Text] [Related]
13. Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas.
Qiao XW; Qiu L; Chen YJ; Meng CT; Sun Z; Bai CM; Zhao DC; Zhang TP; Zhao YP; Song YL; Wang YH; Chen J; Lu CM
BMC Endocr Disord; 2014 Aug; 14():64. PubMed ID: 25099181
[TBL] [Abstract][Full Text] [Related]
14. Clinical usefulness of plasma chromogranin a in pancreatic neuroendocrine neoplasm.
Paik WH; Ryu JK; Song BJ; Kim J; Park JK; Kim YT; Yoon YB
J Korean Med Sci; 2013 May; 28(5):750-4. PubMed ID: 23678268
[TBL] [Abstract][Full Text] [Related]
15. Baseline plasma chromogranin A levels in patients with well-differentiated neuroendocrine tumors of the pancreas: A potential predictor of postoperative recurrence.
Nanno Y; Toyama H; Matsumoto I; Otani K; Asari S; Goto T; Ajiki T; Zen Y; Fukumoto T; Ku Y
Pancreatology; 2017; 17(2):291-294. PubMed ID: 28043759
[TBL] [Abstract][Full Text] [Related]
16. Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors.
Dam G; Grønbæk H; Sorbye H; Thiis Evensen E; Paulsson B; Sundin A; Jensen C; Ebbesen D; Knigge U; Tiensuu Janson E
Neuroendocrinology; 2020; 110(3-4):217-224. PubMed ID: 31578011
[TBL] [Abstract][Full Text] [Related]
17. Blood Molecular Genomic Analysis Predicts the Disease Course of Gastroenteropancreatic Neuroendocrine Tumor Patients: A Validation Study of the Predictive Value of the NETest®.
van Treijen MJC; van der Zee D; Heeres BC; Staal FCR; Vriens MR; Saveur LJ; Verbeek WHM; Korse CM; Maas M; Valk GD; Tesselaar MET
Neuroendocrinology; 2021; 111(6):586-598. PubMed ID: 32492680
[TBL] [Abstract][Full Text] [Related]
18. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution.
Massironi S; Rossi RE; Casazza G; Conte D; Ciafardini C; Galeazzi M; Peracchi M
Neuroendocrinology; 2014; 100(2-3):240-9. PubMed ID: 25428270
[TBL] [Abstract][Full Text] [Related]
19. Circulating Chromogranin A as A Marker for Monitoring Clinical Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors.
Tian T; Gao J; Li N; Li Y; Lu M; Li Z; Lu Z; Li J; Shen L
PLoS One; 2016; 11(5):e0154679. PubMed ID: 27159453
[TBL] [Abstract][Full Text] [Related]
20. Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors.
Chou WC; Chen JS; Hung YS; Hsu JT; Chen TC; Sun CF; Lu CH; Hwang TL
Anticancer Res; 2014 Oct; 34(10):5661-9. PubMed ID: 25275071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
